Novo Nordisk A/S ADR (NVO)
73.60 x 200 73.75 x 100
Post-market by (Cboe BZX)
73.60 -1.73 (-2.30%) 03/25/25 [NYSE]
73.60 x 200 73.75 x 100
Post-market 73.76 +0.16 (+0.22%) 19:53 ET
for Tue, Mar 25th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Sales | 42,108,430 | 33,724,300 | 25,056,690 | 22,401,280 | 19,448,130 |
Cost of Goods | 6,455,690 | 5,193,078 | 4,028,237 | 3,763,988 | 3,206,782 |
Gross Profit | 35,652,750 | 28,531,220 | 21,028,450 | 18,637,290 | 16,241,340 |
Operating Expenses | 17,044,280 | 13,637,550 | 10,435,730 | 9,308,020 | 7,950,020 |
Operating Income | 18,609,150 | 14,893,750 | 10,592,950 | 9,330,261 | 8,292,104 |
Interest Expense | 1,065,170 | 122,694 | 847,618 | 389,954 | 401,997 |
Other Income | 898,720 | 427,614 | 33,848 | 459,321 | 249,409 |
Pre-tax Income | 18,442,700 | 15,198,670 | 9,779,180 | 9,399,628 | 8,139,516 |
Income Tax | 3,799,435 | 3,047,893 | 1,916,839 | 1,801,489 | 1,683,974 |
Net Income Continuous | 14,643,260 | 12,150,770 | 7,862,340 | 7,598,139 | 6,455,542 |
Net Income | $14,643,260 | $12,150,770 | $7,862,340 | $7,598,139 | $6,455,542 |
EPS Basic Total Ops | 3.29 | 2.71 | 1.74 | 1.65 | 1.38 |
EPS Basic Continuous Ops | 3.29 | 2.71 | 1.74 | 1.65 | 1.38 |
EPS Diluted Total Ops | 3.28 | 2.70 | 1.73 | 1.65 | 1.38 |
EPS Diluted Continuous Ops | 3.28 | 2.70 | 1.73 | 1.65 | 1.38 |
EPS Diluted Before Non-Recurring Items | 3.28 | 2.70 | 1.73 | 1.65 | 1.38 |
EBITDA(a) | $21,379,670 | $16,260,510 | $11,635,410 | $10,288,840 | $9,173,462 |